Elie Traer, MD
Hematology & Oncology · Portland, ORNPI 1295933729
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $53,534 of the $72,346 with a category attached, or 74.0%. It is spread thinly across 17 manufacturers, the largest accounting for just 14.6%. Reporting peaked in 2019 at $19,655 and has fallen 59.1% since, to $8,035 in 2025. Among hematology & oncology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $640.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$11K
- Incyte Corporation$11K
- Agios Pharmaceuticals, Inc.$8K
- Daiichi Sankyo Inc.$8K
- Astellas Pharma US Inc$8K
- AbbVie$8K
- plus $19K from 11 others
Across 798 payments — averaging $7995.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2.3M
- Incyte Corporation$1.2M
- Astellas Pharma Global Development$788K
- Otsuka Pharmaceutical Co., Ltd.$759K
- AstraZeneca$257K
- Servier Bioinnovation$195K
- plus $885K from 14 others
What the payments were for
- Consulting fees$53,53474%
- Speaking & faculty fees$6,7409%
- Travel & lodging$7,24810%
- Food & beverage$4,8247%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 11 | $10,594 |
| Incyte Corporation | 11 | $10,559 |
| Agios Pharmaceuticals, Inc. | 14 | $8,345 |
| Daiichi Sankyo Inc. | 11 | $8,286 |
| Astellas Pharma US Inc | 9 | $8,028 |
| AbbVie | 17 | $7,644 |
| Syndax Pharmaceuticals, Inc. | 7 | $4,451 |
| Astellas Pharma Global Development | 2 | $4,250 |
| Rigel Pharmaceuticals, Inc. | 7 | $3,681 |
| Genentech, Inc. | 8 | $2,738 |
| Stemline Therapeutics Inc. | 5 | $2,556 |
| AstraZeneca | 4 | $443 |
| Bristol Myers Squibb | 2 | $285 |
| Genentech USA, Inc. | 2 | $171 |
| E.r. Squibb & Sons, L.L.C. | 1 | $148 |
| Taiho Oncology, Inc. | 1 | $101 |
| Jazz Pharmaceuticals Inc. | 1 | $66 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$72,346 in reported general payments places this provider in the 90th percentile of 112 hematology & oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 91 | $1,451,024 |
| TibsovoIvosidenib | 37 | $1,179,795 |
| OjjaaraMomelotinib Dihydrochloride | 34 | $918,599 |
| IdhifaEnasidenib Mesylate | 14 | $483,410 |
| VenclextaVenetoclax | 26 | $82,370 |
| PegasysPeginterferon Alfa-2a | 22 | $63,576 |
| Posaconazole | 15 | $13,977 |
| EliquisApixaban | 12 | $7,311 |
| Voriconazole | 15 | $4,526 |
| Cefpodoxime Proxetil | 14 | $2,720 |
| Acyclovir | 77 | $1,113 |
| Rosuvastatin Calcium | 15 | $838 |
| Cyclosporine ModifiedCyclosporine, Modified | 11 | $664 |
| Hydroxyurea | 26 | $639 |
| Omeprazole | 25 | $241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $10,559 | $1,451,02491 claims |
| Servier Pharmaceuticals LLCTibsovo | $10,594 | $1,179,79537 claims |
| Bristol Myers SquibbIdhifa | $285 | $483,41014 claims |
| AbbVieVenclexta | $7,644 | $82,37026 claims |
| Genentech, Inc.Pegasys | $2,738 | $63,57622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 hematology & oncology providers in Oregon.
Other hematology & oncology in Portland
- Brian DrukerPortland$1.9M
- Jay AndersenPortland$196K
- Richard MaziarzPortland$174K
- Tibor KovacsovicsPortland$119K
- Jeffrey MenashePortland$38K
- Michael HeinrichPortland$37K
- Lucy LangerPortland$18K
- Miklos SimonPortland$13K
- Alexandra SokolovaPortland$12K
- Jacqueline VukyPortland$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.